Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

Since the advent of modern surgery for pancreatic cancer, clinicians have recognized this cancer's propensity to recur locally, metastasize, and cause death. Despite significant efforts to improve patient outcomes with better adjuvant therapy, only modest gains in survival have been observed. An alternative strategy of neoadjuvant therapy followed by surgery has the potential to improve patient selection and survival, and expand the pool of patients eligible for curative surgery. This article summarizes large, randomized trials of adjuvant therapy, explains the limitations imposed by up-front surgery, and suggests neoadjuvant therapy as a rational alternative to initial surgery and adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)95-111
Number of pages17
JournalSurgical Clinics of North America
Volume98
Issue number1
DOIs
StatePublished - Feb 2018

Keywords

  • Adjuvant therapy
  • Borderline resectable pancreatic cancer
  • Chemotherapy
  • Locally advanced pancreatic cancer
  • Neoadjuvant therapy
  • Preoperative therapy
  • Resectable pancreatic cancer
  • Resection

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?'. Together they form a unique fingerprint.

Cite this